Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2023-10-02
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Tapioca-based FiberSMART® Compared to a Glucose Challenge or Water Control on Postprandial Glycemia in Healthy Subjects: An Acute Randomized Controlled Trial
NCT07075822
Effect of Resistant Starch Type 4 on Glycemia and Insulin Sensitivity in Young Adults
NCT00687960
Resistant Starch on Glucose and Insulin Sensitivity in Individuals With Type 2 Diabetes
NCT00691249
Comparison of Different Types of Resistant Starch
NCT00930956
Effects of Resistant Starch in a Beverage on Post-prandial Glycemic and Insulinemic Responses
NCT02161250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Native Starch, then Processed Starch
Participants will first receive the Commercial Native Starch in a fasting state in one clinical visit. After a washout of \>24 hours, the participants will then receive the Extrusion Processed Starch in a fasting state in one clinical visit.
Commercial native starch without processing
A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
Modified starch with extrusion processing
A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
Processed Starch, then Native Starch
Participants will first receive the Extrusion Processed Starch in a fasting state in one clinical visit. After a washout of \>24 hours, the participants then will receive the Commercial Native Starch in a fasting state in one clinical visit.
Commercial native starch without processing
A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
Modified starch with extrusion processing
A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Commercial native starch without processing
A food-grade commercial native starch without processing that has been rehydrated into a pudding for oral consumption.
Modified starch with extrusion processing
A food-grade modified starch with extrusion processing that has been rehydrated into a pudding for oral consumption.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* eligible to receive income in Canada.
Exclusion Criteria
* any known food allergies or intolerances to the investigational product
* medications known to affect glucose tolerance -but stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable
* known history of diabetes mellitus or the use of anti-hyperglycemic drugs or insulin to treat diabetes and related conditions
* any major medical or surgical events requiring hospitalization within the preceding 3 months
* the presence of disease or drug(s) which influence digestion and absorption of nutrients
* the short-term use of systemic steroids or atypical antipsychotics (\<4 weeks) (all of which have major effects on glucose and metabolism and body fat distribution)
* any other medications or conditions which might, in the opinion of the Medical Director of INQUIS Clinical Research Ltd. (INQUIS), either 1) make participation dangerous to the subject or to others, or 2) affect the results
* any subject who cannot or will not comply with the experimental procedures or do not follow INQUIS safety guidelines
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Saskatchewan
OTHER
INQUIS Clinical Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas MS Wolever, MD, PhD, DM (Oxon)
Role: PRINCIPAL_INVESTIGATOR
INQUIS Clinical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INQUIS Clinical Research Ltd.
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INQ-2330
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.